Yusra B. Medik

Stem Cell Origin of Cancer: Biological Principles and Clinical Strategies for Chemoprevention and Maintenance Therapy in Cancer Care

Yusra B. Medik, Sehrish Sardar, Jaskirat Sethi, Marcelo Puppo Bigarella et autres

In this Perspective, we discuss a stem cell origin of cancer and consider the biological principles and clinical strategies for chemoprevention in cancer care. We examine the role of vitamin D, tumor microenvironment, and GLP-1R agonists in chemoprevention and maintenance therapy. If …

us (code pays fourni par la source)

Bilateral germ cell tumor of the testis (TGCT): Implications for a stem cell versus genetic origin of cancers.

Jamaal Christopher Jackson, Eduardo Vilar Sanchez, Yusra B. Medik, Sehrish Sardar et autres

5037 Background: Bilateral TGCT provides a unique opportunity to elucidate a stem cell versus genetic origin of cancer. Comparison of the epigenetics and genetics of disparate tumors in either synchronous or metachronous bilateral TGCT from the same patients is feasible and may …

us (code pays fourni par la source)

Correction to “Nanoparticle Drug Delivery Can Reduce the Hepatotoxicity of Therapeutic Cargo”

Feifei Yang, Yusra B. Medik, Liantao Li, Xi Tian et autres

Our published article contained two errors in Figure 3.In Figure 3b, the representative images of "untreated" 24 and 72 h were mistakenly chosen from wrong experimental groups, leading to overlapping images with "untreated 72 h" and 5b "non-depletion free 72 h".Similarly, Figure …

Nanoparticle Drug Delivery Can Reduce the Hepatotoxicity of Therapeutic Cargo

Hossein Sendi, Yusra B. Medik, Liantao Li, Andrew Zhuang Wang et autres

Hepatotoxicity is a key concern in the clinical translation of nanotherapeutics because preclinical studies have consistently shown that nanotherapeutics accumulates extensively in the liver. However, clinical-stage nanotherapeutics have not shown increased hepatotoxicity. Factors that can contribute to the hepatotoxicity of nanotherapeutics beyond …

us (code pays fourni par la source)

Time to treatment initiation of lung cancer and contributing factors from 2015-2020 utilizing Surveillance, Epidemiology and End Results program database.

Mariela Di Vanna, Saria Qaiser, Shreya Shambhavi, Sheilabi Seeburun et autres

1540 Background: Time from diagnosis of cancer to definitive therapy, or time to treatment initiation (TTI), has significant impact on prognosis. Kohorana et al performed an observational study in 2019 that found that TTI has increased in the United States with an …

us (code pays fourni par la source)

STAT3 protects hematopoietic stem cells by preventing activation of a deleterious autocrine type-I interferon response

Bhakti Patel, Yifan Zhou, Rachel Lauren Babcock, Feiyang Ma et autres

us (code pays fourni par la source)

Efficacy of checkpoint inhibitors in hospitalized patients with cancer.

Yusra B. Medik, Vinit Kumar Singh, Marina Alsabaawy, G. Gerbino et autres

e14687 Background: Pembrolizumab is approved by FDA in 2014 to treat metastatic melanoma. Use of immune check point inhibitors (ICI) has been expanding in multiple cancer types including non-small cell lung cancer since then. In this mini case series, we will evaluate …

us (code pays fourni par la source)

STAT3 protects HSCs from intrinsic interferon signaling and loss of long-term blood-forming activity

Bhakti Patel, Yifan Zhou, Rachel Lauren Babcock, Feiyang Ma et autres

Abstract STAT3 function in hematopoietic stem and progenitor cells (HSPCs) has been difficult to discern as Stat3 deficiency in the hematopoietic system induces systemic inflammation, which can impact HSPC activity. To address this, we established mixed bone marrow (BM) chimeric mice with …

us (code pays fourni par la source)

STAT3 Protects Hematopoietic Stem and Progenitor Cell Function in Non-Inflamed Conditions

Bhakti Patel, Yifan Zhou, Rachel Lauren Babcock, Feiyang Ma et autres

The transcriptional regulator STAT3 has well established anti-inflammatory functions in mature myeloid cells by preventing excessive pro-inflammatory factor production in response to Toll-like receptor agonists or the gut microbiota. However, this role has precluded understanding of STAT3 function in maintaining hematopoietic stem …

us (code pays fourni par la source)

Intestinal toxicity to CTLA-4 blockade driven by IL-6 and myeloid infiltration

Yifan Zhou, Yusra B. Medik, Bhakti Patel, Daniel B. Zamler et autres

Immune checkpoint blockade (ICB) has revolutionized cancer treatment, yet quality of life and continuation of therapy can be constrained by immune-related adverse events (irAEs). Limited understanding of irAE mechanisms hampers development of approaches to mitigate their damage. To address this, we examined …

us, cn (code pays fourni par la source)

Management of Pregnancy Associated Breast Cancer: a Review

Stephanie Ng, Kristina Shaffer, Trishala Meghal, Lilian Thomas-Harris et autres

us (code pays fourni par la source)

Abstract 5545: Intestinal toxicity to CTLA-4 blockade driven by IL-6 and myeloid infiltration

Yifan Zhou, Yusra B. Medik, Bhakti Patel, Daniel B. Zamler et autres

Abstract Immunotherapies such as anti-CTLA-4 immune checkpoint blockade (ICB) have revolutionized cancer treatment, yet quality of life and continuation of therapy can be constrained by off-target tissue damage or immune-related adverse events (irAEs). At present, there is limited understanding of irAE mechanisms, …

us, cn (code pays fourni par la source)